Vancouver, British Columbia–(Newsfile Corp. – March 11, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FSE: 6UF) (“NeonMind“) is pleased to announce that on March 10, 2021 NeonMind engaged Certara®, the global leader in model-informed drug development to provide strategic integrated drug development support for the investigation of NeonMind’s psilocybin based drug candidates for the…

Source

Previous articleBetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003
Next articleDemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK

RELATED ARTICLESMORE FROM AUTHOR